These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23924445)

  • 21. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review.
    Ghorbani F; Abbaszadeh H; Dolatabadi JEN; Aghebati-Maleki L; Yousefi M
    Biosens Bioelectron; 2019 Oct; 142():111484. PubMed ID: 31284103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density.
    Chen Y; Jiang X; Liu R; Zhang Z; Luo F; Qi S; Xu Y
    Med Sci Monit; 2019 Aug; 25():6230-6235. PubMed ID: 31424055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond PSA: The Role of Prostate Health Index (phi).
    Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for prostate cancer: have we resolved the controversy?
    Zhu X; Roobol MJ; Schröder FH
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):121-6. PubMed ID: 20489646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
    Zlotta A; Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A201-5. PubMed ID: 10523893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical significance of prostate-specific antigen].
    Tveter KJ; Otnes B
    Tidsskr Nor Laegeforen; 1994 Jan; 114(2):160-2. PubMed ID: 7510073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
    McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
    Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasmonic nanostructures for SERRS multiplexed identification of tumor-associated antigens.
    Meneghetti M; Scarsi A; Litti L; Marcolongo G; Amendola V; Gobbo M; Di Chio M; Boscaini A; Fracasso G; Colombatti M
    Small; 2012 Dec; 8(24):3733-8. PubMed ID: 22927257
    [No Abstract]   [Full Text] [Related]  

  • 30. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen in screening for prostate cancer.
    Mayer FJ; Crawford ED
    West J Med; 1994 Feb; 160(2):168. PubMed ID: 7512780
    [No Abstract]   [Full Text] [Related]  

  • 32. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
    Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW
    Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
    PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mass screening for prostate cancer.
    Andersson L
    Acta Oncol; 1998; 37(6):513-4. PubMed ID: 9860308
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate-specific antigen and screening for prostate cancer: much ado about something?
    Pollack HM; Resnick MI
    Radiology; 1993 Nov; 189(2):353-6. PubMed ID: 7692463
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.
    Borno HT; Kuo Lin T; Odisho AY; Desai A; Koshkin V; Werner K; Legaspi N; Bucknor M; Bell A; Zhang S; Hope TA
    Cancer Med; 2021 Jan; 10(1):62-69. PubMed ID: 33247633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The controversy over PSA testing: has anything changed?
    Johns Hopkins Med Lett Health After 50; 2009 Aug; 21(6):1-2. PubMed ID: 19722309
    [No Abstract]   [Full Text] [Related]  

  • 38. Early detection of prostate cancer: European Association of Urology recommendation.
    Heidenreich A; Abrahamsson PA; Artibani W; Catto J; Montorsi F; Van Poppel H; Wirth M; Mottet N;
    Eur Urol; 2013 Sep; 64(3):347-54. PubMed ID: 23856038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer.
    Young CY; Seay T; Hogen K; Charlesworth MC; Roche PC; Klee GG; Tindall DJ
    Prostate Suppl; 1996; 7():17-24. PubMed ID: 8950360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for prostate cancer.
    Brawer MK
    Semin Surg Oncol; 2000; 18(1):29-36. PubMed ID: 10617894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.